114 related articles for article (PubMed ID: 10078700)
1. Renal cysteine conjugate beta-lyase and compound A nephrotoxicity: minimal evidence for an association.
Njoku DB; Martin JL; Pohl LR
Anesthesiology; 1999 Mar; 90(3):921-2. PubMed ID: 10078700
[No Abstract] [Full Text] [Related]
2. Role of the renal cysteine conjugate beta-lyase pathway in inhaled compound A nephrotoxicity in rats.
Kharasch ED; Hoffman GM; Thorning D; Hankins DC; Kilty CG
Anesthesiology; 1998 Jun; 88(6):1624-33. PubMed ID: 9637657
[TBL] [Abstract][Full Text] [Related]
3. Role of renal cysteine conjugate beta-lyase in the mechanism of compound A nephrotoxicity in rats.
Kharasch ED; Thorning D; Garton K; Hankins DC; Kilty CG
Anesthesiology; 1997 Jan; 86(1):160-71. PubMed ID: 9009951
[TBL] [Abstract][Full Text] [Related]
4. Immunochemical evidence against the involvement of cysteine conjugate beta-lyase in compound A nephrotoxicity in rats.
Njoku DB; Pohl LR; Sokoloski EA; Marchick MR; Borkowf CB; Martin JL
Anesthesiology; 1999 Feb; 90(2):458-69. PubMed ID: 9952153
[TBL] [Abstract][Full Text] [Related]
5. Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate beta-lyase.
Jin L; Baillie TA; Davis MR; Kharasch ED
Biochem Biophys Res Commun; 1995 May; 210(2):498-506. PubMed ID: 7755627
[TBL] [Abstract][Full Text] [Related]
6. Role of cytochrome P4503A in cysteine S-conjugates sulfoxidation and the nephrotoxicity of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in rats.
Sheffels P; Schroeder JL; Altuntas TG; Liggitt HD; Kharasch ED
Chem Res Toxicol; 2004 Sep; 17(9):1177-89. PubMed ID: 15377151
[TBL] [Abstract][Full Text] [Related]
7. Evidence for metabolism of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), a sevoflurane degradation product, by cysteine conjugate beta-lyase.
Spracklin DK; Kharasch ED
Chem Res Toxicol; 1996 Jun; 9(4):696-702. PubMed ID: 8831812
[TBL] [Abstract][Full Text] [Related]
8. Nephrotoxicity of the glutathione and cysteine S-conjugates of the sevoflurane degradation product 2-(fluoromethoxy)-1,1,3,3, 3-pentafluoro-1-propene (Compound A) in male Fischer 344 rats.
Iyer RA; Baggs RB; Anders MW
J Pharmacol Exp Ther; 1997 Dec; 283(3):1544-51. PubMed ID: 9400032
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of compound A by renal cysteine-S-conjugate beta-lyase is not the mechanism of compound A-induced renal injury in the rat.
Martin JL; Laster MJ; Kandel L; Kerschmann RL; Reed GF; Eger EI
Anesth Analg; 1996 Apr; 82(4):770-4. PubMed ID: 8615496
[TBL] [Abstract][Full Text] [Related]
10. Cysteine conjugate beta-lyase-dependent biotransformation of the cysteine S-conjugates of the sevoflurane degradation product 2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene (compound A).
Iyer RA; Anders MW
Chem Res Toxicol; 1997 Jul; 10(7):811-9. PubMed ID: 9250416
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line.
Altuntas TG; Zager RA; Kharasch ED
Toxicol Appl Pharmacol; 2003 Nov; 193(1):55-65. PubMed ID: 14613716
[TBL] [Abstract][Full Text] [Related]
12. Cysteine conjugate beta-lyase-dependent metabolism of compound A (2-[fluoromethoxy]-1,1,3,3,3-pentafluoro-1-propene) in human subjects anesthetized with sevoflurane and in rats given compound A.
Iyer RA; Frink EJ; Ebert TJ; Anders MW
Anesthesiology; 1998 Mar; 88(3):611-8. PubMed ID: 9523802
[TBL] [Abstract][Full Text] [Related]
13. Biotransformation of L-cysteine S-conjugates and N-acetyl-L-cysteine S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human kidney in vitro: interindividual variability in N-acetylation, N-deacetylation, and beta-lyase-catalyzed metabolism.
Gul Altuntas T; Kharasch ED
Drug Metab Dispos; 2002 Feb; 30(2):148-54. PubMed ID: 11792683
[TBL] [Abstract][Full Text] [Related]
14. Influence of sevoflurane on the metabolism and renal effects of compound A in rats.
Kharasch ED; Schroeder JL; Sheffels P; Liggitt HD
Anesthesiology; 2005 Dec; 103(6):1183-8. PubMed ID: 16306730
[TBL] [Abstract][Full Text] [Related]
15. Glutathione S-conjugation of the sevoflurane degradation product, fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human liver, kidney, and blood in vitro.
Altuntas TG; Kharasch ED
Toxicol Appl Pharmacol; 2001 Dec; 177(2):85-93. PubMed ID: 11740907
[TBL] [Abstract][Full Text] [Related]
16. [Compound A: toxicology and clinical relevance].
Kharasch ED
Anaesthesist; 1998 Nov; 47 Suppl 1():S7-10. PubMed ID: 9893874
[TBL] [Abstract][Full Text] [Related]
17. Nephrotoxicity of halogenated inhalational anaesthetics: fictions and facts.
Reichle FM; Conzen PF; Peter K
Eur Surg Res; 2002; 34(1-2):188-95. PubMed ID: 11867922
[No Abstract] [Full Text] [Related]
18. L-alanine-glyoxylate aminotransferase II of rat kidney and liver mitochondria possesses cysteine S-conjugate beta-lyase activity: a contributing factor to the nephrotoxicity/hepatotoxicity of halogenated alkenes?
Cooper AJ; Krasnikov BF; Okuno E; Jeitner TM
Biochem J; 2003 Nov; 376(Pt 1):169-78. PubMed ID: 12859250
[TBL] [Abstract][Full Text] [Related]
19. Cysteine conjugate beta-lyase-dependent biotransformation of the cysteine S-conjugates of the sevoflurane degradation product compound A in human, nonhuman primate, and rat kidney cytosol and mitochondria.
Iyer RA; Anders MW
Anesthesiology; 1996 Dec; 85(6):1454-61. PubMed ID: 8968194
[TBL] [Abstract][Full Text] [Related]
20. Identification in rat bile of glutathione conjugates of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether, a nephrotoxic degradate of the anesthetic agent sevoflurane.
Jin L; Davis MR; Kharasch ED; Doss GA; Baillie TA
Chem Res Toxicol; 1996 Mar; 9(2):555-61. PubMed ID: 8839062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
